What you believe and what is fact are two entirely different things. It is easy to find fault with sunshine. This is why you sleep fitfully at night. Accept the facts and move on with your life for your own health.
Like I was saying, there remain a number of small, undiscovered biotech firms that may contribute to the pan flu vaccine story.
This product candidate appears to do what I believe Allovectin was originally intended to do- but they got confused and used HLA-B7 instead of the T cell receptor co-stimulatory molecules B7-1 and B7-2.
Very interesting and potentially important.
Pretty direct competition for the cancer application(s).
Press Release Source: CEL-SCI Corporation
CEL-SCI Files Patent for Prevention/Treatment of Bird (Avian) Flu Tuesday April 4, 9:45 am ET
VIENNA, Va., April 4 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION (Amex: CVM - News) announces that it has filed a provisional U.S. patent application covering its drug CEL-1000 for the prevention/treatment of bird flu and/or as an adjuvant to be included in a bird flu vaccine. Geert Kersten, Chief Executive Officer of CEL-SCI said, "By filing this patent in the U.S., we are preserving our rights to file patents on this invention world-wide."
CEL-1000, when used as a single adjuvant (enhancer of a vaccine) or in combination with other adjuvants, potentiates Th1 (cellular) and innate (earliest stage) immune responses and protects animals from viral and parasitic challenge. CEL-1000 provides antigen-independent (i.e., non-disease specific) and broad-spectrum protection upon challenge with the disease causing agent(s), which is important against the bird flu virus since it exhibits a high mutation rate.
CEL-1000, is a patented defined amino acid sequence derived from the beta chain of human MHC-II, which itself is a modified version of a human immune- based protein known to bind to both human and mouse immune cells and appears to act by enhancing the host's protective immune response. It is a defined peptide, which binds to the CD4 and/or likely a related molecule LAG-3 on dendritic cells, macrophages and T cells, thereby promoting the release of cytokines responsible for activating a protective Th1 immune response (e.g., IL-12 and upon challenge IFN-gamma).
CEL-SCI Corporation is developing new immune system based treatments for cancer and infectious diseases. The Company has operations in Vienna, Virginia and Baltimore, Maryland.